Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


SB012 for the Treatment of Active Ulcerative Colitis (SECURE): a Prospective, Single-centre, Randomised, Double-blind, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy, Pharmacokinetics, Tolerability, and Safety of SB012 Enema Administered Once Daily

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Ulcerative colitis (UC) represents one of the major entities of idiopathic inflammatory
bowel diseases which are defined as chronically relapsing inflammations of the
gastrointestinal tract not due to specific pathogens. It is characterised by a superficial,
continuous mucosal inflammation, which predominantly affects the large intestine. The
clinical course is typically marked by periods of asymptomatic remission punctuated by
unpredictable recurrent attacks. The symptoms of the patients are marked by persistent
diarrhoea with severe faecal urgency and often incontinence, rectal bleeding, abdominal
cramping and weight loss.

Uncontrolled activation of mucosal effector T cells has been identified as the main
pathogenic mechanism involved in the initiation and perpetuation of intestinal inflammatory

Patients with moderate UC are initially treated with mesalazine, applied both orally and
rectally. If symptoms do not improve, systemic corticosteroids are to be administered.
Patients who do not respond to systemic corticosteroids may become eligible for treatment
with a calcineurin inhibitor or an anti-tumor necrosis factor (TNF)α antibody.
Alternatively, patients may have to undergo major colorectal surgery.

Patients who do not adequately respond to these treatment strategies exhibit serious
drawbacks. Colorectal surgery may result in a severely compromised quality of life.

Therefore, patients with moderate or severe UC may significantly benefit from new
therapeutic alternatives.

The transcription factor GATA-3 is an interesting target for a novel therapeutic strategy in

GATA-3 is the key regulation factor of Th2-driven immune responses. It is indispensable for
the differentiation and activation of Th2 cells, integrates Th2 signals, and induces Th2
cytokine expression. Results of a recent clinical trial in children showed that GATA-3 is
involved in the pathogenesis of the acute phase of UC.

The investigational product SB012 contains the DNAzyme hgd40 that targets GATA-3. By
cleaving GATA-3 mRNA hgd40 reduces specific cytokine production and thereby reduces key
features of mucosal inflammation.

DNAzymes are completely generated by chemical synthesis, not by use of any living organism
and are therefore not biological drugs.

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of the
topical formulation SB012 available in a concentration of 7.5mg/ml hgd40 in 30ml PBS once
daily as a ready-for-use enema in patients with active UC.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language


end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00007193
  •   2015/06/09
  •   2014/04/30
  •   no
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT02129439  (
  •   SB012/01/2013  (Sterna Biologicals GmbH & Co. KG)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Colitis, Ulcerative
  •   K51 -  Ulcerative colitis
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: SB012
  •   Drug: Placebo
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   investigator/therapist, assessor
  •   Placebo
  •   Treatment
  •   Parallel
  •   I-II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Efficacy: Total Mayo score (4 weeks comparison); time frame: Baseline (Visit 2) to day 28 (Visit 7) (28 days); Change in Total Mayo score after 4 weeks of treatment compared to baseline value in the active treatment group (SB012) versus placebo.
The Total Mayo score is a 13-point ordinal scale for the assessment of concurrent severity of ulcerative colitis. It comprises four components: stool frequency, rectal bleeding, endoscopic findings and physician's global assessment of disease severity. Each component has four grades ranging from 0 to 3. The Total Mayo score ranges from 0 to 12, with 12 representing the most severe disease.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Efficacy: Total Mayo score (8 weeks comparison); time frame: Baseline (Visit 2) to End-of-Study Visit10 (56 days); Change in Total Mayo score 8 weeks after start of treatment compared to baseline value in the active treatment group (SB012) versus placebo.
- Efficacy: Endoscopic Mayo score (4 and 8 weeks comparison); time frame: Baseline (Visit 2) to Visit 7 and Visit 10 (28 and 56 days); Change in Endoscopic Mayo score 4 and 8 weeks after start of treatment compared to baseline value in the active treatment group (SB012) versus placebo.
The Endoscopic Mayo score represents a subscore of the Total Mayo score and consists of the endoscopic findings. It ranges from 0 to 3.
Normal or inactive disease 0 Mild disease (erythema, decreased vascular pattern, mild friability) 1 Moderate disease (marked erythema, absent vascular pattern, friability, erosions) 2 Severe disease (spontaneous bleeding, ulceration) 3
- Efficacy/Pharmacodynamics: Glucocorticoid consumption; time frame: Baseline (Visit 2) to day 56 End of Study Visit 10 (56 days); Change in systemic glucocorticoid consumption (measured as Defined Daily Dose) 8 weeks after start of treatment compared to baseline value in the active treatment group (SB012) versus placebo.
- Safety: Treatment Emergent Adverse Events (AE) and Serious Adverse Events (SAE); time frame: Visit 1 (Screening) to Visit 10 (End of Study - 56 days) or Visit X (Early Study Termination); Number of treatment-emergent AEs and SAEs in the active treatment group (SB012) versus placebo in patient´s overall study period.

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2014/04/30
  •   18
  •   [---]*
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   75   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

The trial population consists of adult subjects of both sexes with active ulcerative
colitis aged 18 to 75 years.

The main inclusion criteria comprise:

- Fully capable to give informed consent.

- Mentally able to understand the nature, significance, implications and risks of the
clinical trial and to follow instructions of the trial staff.

- Written informed consent

- Clinical Mayo Score of ≥3

- Total Mayo Score of ≥6

- Endoscopic Mayo score ≥2 in the sigmoid

- Body mass index ≥18.0 to ≤29.0kg/m2 and body weight ≥50 to ≤100kg

- Negative urine pregnancy test (female subject only)

- Using two methods of contraception

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Colectomy and presence of ileal pouch-anal anastomosis or ileorectal anastomosis

- Diagnosis of ulcerative proctitis, fulminant colitis, toxic megacolon, of colitis
indeterminata or Crohn's disease

- Ileostoma

- Anti-TNFα treatment with adalimumab, certolizumab, etanercept, golimumab, or
infliximab ≤4 weeks prior to screening visit.

- Change in systemic glucocorticoid treatment ≤1 weeks prior to screening visit

- Change in 5-Aminosalicylic Acid (ASA) therapy ≤1 week prior to screening visit

- Start of treatment with an immunosuppressive agent ≤3 months prior to screening visit

- Change in treatment with an immunosuppressive agent ≤4 weeks prior to baseline visit

- Planned concomitant therapeutic administration of suppositories or foams or enema
other than the IMP.

- Impaired blood coagulation (Quick value <50% and/or partial thromboplastin time (PTT)
>55sec and/or platelet count <50.000/μl.)

- Signs of renal insufficiency

- Signs of hepatic insufficiency.

- Current treatment with drugs of high hepatotoxic potential.

- Evidence of recent alcohol abuse.

- Acute or chronic heart failure with NYHA functional class III or IV.

- Known active tuberculosis.

- Known acute serious infections or sepsis.

- Known current malignant disease.

- Positive blood test against HBs antigen, anti-HBc antibodies, anti-HCV antibodies or
anti-HIV-1/2 antibodies.

- Known opportunistic infections including invasive fungal infections.

- Known hypersensitivity to the IMP or any of their formulation ingredients.

- Any condition that is thought to reduce the compliance to cooperate with the trial

- Employee of the department of the investigator, of the Center for Clinical Studies
(CCS) or of the sponsor.

- Prior participation in this clinical trial.

- Participation in an interventional clinical trial within the last three months (six
months in case of a biological IMP) or be under the exclusion period from another
clinical trial.

- Known or planned absence that may collide with the clinical trial visit schedule.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Sterna Biologicals GmbH & Co. KG
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Department of Medicine 1 - Gastroenterology, Pneumology and Endocrinology, University Clinic Erlangen, Germany
    • Markus F. Neurath, Prof. Dr. 
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Joachim Bille, PhD 
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   1
  •   2014/11/05
* This entry means the parameter is not applicable or has not been set.